Multi-Drug Therapies Vastly Reduce China Leprosy, But Thousands Remain
This article was originally published in PharmAsia News
Leprosy has yet to be eradicated in China, particularly in 10 percent of the country, despite long-term efforts by the country and multi-drug therapies introduced in the 1980s. The secretary-general of the China Leprosy Association said about 1,600 new cases are reported every year, two percent of them children. The disease is no longer considered a public health threat, but the Ministry of Health estimates there are still 6,300 leprosy patients in the country. China counted 500,000 cases in 1949. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.